Why the study?
Does aspirin reduce the incidence of ventricular fibrillation during nonthrombotic coronary occlusion in a canine model?
Population
53 anesthetized dogs with nonthrombotic coronary occlusion induced by a balloon catheter
Comparison
Aspirin 600 mg/dog daily for seven days vs Untreated control group
Design
Preclinical
Follow-up
4 hours
Authors
Loading...
Does not support clinical use; leaves open whether aspirin's antiarrhythmic effects in canine ischemia translate to humans.
Does aspirin reduce the incidence of ventricular fibrillation during nonthrombotic coronary occlusion in a canine model?
Aspirin demonstrates direct antiarrhythmic effects during myocardial ischemia independent of its antithrombotic properties, potentially mediated by metabolic and electrolyte shifts.
Moschos et al. (1978) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: